



NewTherapiesSubgroup

Agenda

May 17th 2016 12.30 pm – 2.30 pm

Central Manchester Trust, Pharmacy Dept.
Inpatient pharmacy meeting room.



Declarations of Interest (new declarations only)

Apologies

Item	Supporting papers enclosed
1) Minutes March Meeting	Item 1
2) Matters arising	Item 2
2a) PCSK-9 Inhibitors NICE FADs Evolocumab https://www.nice.org.uk/guidance/GID-TAG498/documents/final-appraisal-determination-document Alirocumab https://www.nice.org.uk/guidance/GID-TAG512/documents/final-appraisal-determination-document	Item 2a NICE TA update
2b) Ulipristal intermittent use draft recommendation & pathway	Item 2b - NTS draft recommendation Consultant feedback & pathway
2c) Idarucizumab (for the reversal of dabigatran) final recommendation	Item 2c NTS recommendation (for information as already signed off by GMMM)
2d) Benepali® (etanercept) biosimilar draft recommendation	Item 2d NTS draft recommendation
2e) Sufentanil sublingual tablet system draft recommendation	Item 2e NTS draft recommendation
2f) Allergic rhinitis pathway for approval (to be used with Dymista® recommendation)	Item 2f NW allergy group pathway
2g) Relvar price reduction and umeclidinium new data	Item 2g Umeclidinium paper & NTS recommendation Relvar letter

3) Ticagrelor for MI (license extension)	Item 3 NTS review document
4) Lesinurad (Zurampic®) for the treatment of Gout	Item 4 NTS review document
5) Brivaracetam (Briviact®)	Item 5 Specialist application Item 5 Review document.
6) Horizon Scanning documents and work plan	Item 6 horizon scanning documents Work plan
7) Updates from other groups	Verbal
a) GMMMG	
b) Interface Prescribing	
c) Formulary Subgroup	
8) AOB	
9) Date of Next Meeting: July 19th 2016 12.30-2.30pm,CMFT	